Metraipolis › archive › dc_425ad72dbb48

Anti-VEGF — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Anti-VEGF
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-09T14:13:11.003Z
SHA-256 of the archived text
0d0b77f9bb80c09b29bec30d6cf911edab90c66248b56f5fb56e0e11449bce33
Stable URL of this page
https://metraipolis.com/documento/dc_425ad72dbb48

How to cite

Anti-VEGF — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Anti-VEGF (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_425ad72dbb48 (Metraipolis archive dc_425ad72dbb48, sha256 0d0b77f9bb80c09b29bec30d6cf911edab90c66248b56f5fb56e0e11449bce33)
BibTeX
@misc{dc425ad72dbb48,
  title = {Anti-VEGF — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Anti-VEGF},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_425ad72dbb48; sha256 0d0b77f9bb80c09b29bec30d6cf911edab90c66248b56f5fb56e0e11449bce33},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Anti-VEGF. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Anti–vascular endothelial growth factor therapy, also known as anti-VEGF () therapy or medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration. They can involve monoclonal antibodies such as bevacizumab, antibody derivatives such as ranibizumab (Lucentis), or orally-available small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF receptors rather than the VEGFs). Both antibody-based compounds and the first three orally available compounds are commercialized. The latter two, axitinib and pazopanib, are in clinical trials. Bergers and Hanahan concluded in 2008 that anti-VEGF drugs can show therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. But, "the benefits are at best transitory and are followed by a restoration of tumour growth and progression." Later studies into the consequences of VEGF inhibitor use have shown that, although they can reduce the growth of primary tumours, VEGF inhibitors can concomitantly promote invasiveness and metastasis of tumours. AZ2171 (cediranib), a multi-targeted tyrosine kinase inhibitor has been shown to have anti-edema effects by reducing the permeability and aiding in vascular normalization. A 2014 Cochrane Systematic Review studied the effectiveness of ranibizumab and pegaptanib, on patients who have macular edema caused by central retinal vein occlusion. Participants in both treatment groups showed improvement in visual acuity measures and a reduction in macular edema symptoms over six months.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Anti-VEGF» — https://en.wikipedia.org/wiki/Anti-VEGF
Wikidata Q23808471: «medication which blocks growth of blood vessels» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q23808471
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Anti-VEGF?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1383229344, consultata il 2026-11-09T14:08:46.620Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: f93c2a1b47d48e8bf26e7ef4137527b5e8c514ec57efa2e4c86fbbfa2e2dc984